Can You Take Gemfibrozil and Repaglinide Together?

No. According to FDA drug labeling information, gemfibrozil and repaglinide should not be used together. Gemfibrozil significantly increases the amount of repaglinide in your bloodstream—by as much as 8.1-fold—which can lead to dangerous levels of the drug and serious low blood sugar. If you are currently taking both medications, do not stop either one on your own; instead, contact your pharmacist or physician immediately to discuss alternatives.

What the Source Says

The interaction between gemfibrozil and repaglinide is classified as contraindicated, meaning the two drugs should not be used together under standard clinical circumstances. The source information comes from FDA drug labeling for repaglinide, which is the authoritative record for how this medication is approved and distributed in the United States.

Specifically, the documented interaction shows that:

• Gemfibrozil causes repaglinide blood levels to increase approximately 8.1-fold
• This large increase happens because gemfibrozil blocks a major enzyme responsible for breaking down repaglinide
• The recommendation is explicit: do not administer repaglinide to patients receiving gemfibrozil

This is not a weak or uncertain interaction. An 8.1-fold increase in drug exposure is substantial and reflects a serious pharmacokinetic interaction—meaning the way your body processes one drug is dramatically altered by the other. FDA drug labeling that uses the word "contraindicated" indicates that the combination poses significant clinical risk and should be avoided.

How to Understand This: The Mechanism and Why It Matters

What is CYP2C8 inhibition?

Your body breaks down most medications using enzymes, which are proteins that act like chemical scissors—they cut and transform drugs so you can eliminate them through urine or bile. One important enzyme family is called the cytochrome P450 system, and CYP2C8 is one member of that family.

Repaglinide relies heavily on the CYP2C8 enzyme to be broken down. When you take repaglinide alone, your body efficiently processes it, and the drug reaches a predictable level in your bloodstream before being cleared. This allows your dose to work as intended.

Gemfibrozil, a medication used to lower cholesterol and triglycerides, is a potent inhibitor of CYP2C8. When gemfibrozil is present in your body, it essentially shuts down or severely slows the enzyme that would normally break down repaglinide. The result is that repaglinide accumulates in your bloodstream instead of being eliminated as expected.

The 8.1-fold increase explained

An 8.1-fold increase means that instead of having, for example, 1 unit of repaglinide in your blood at a given time, you might have 8.1 units. This is not a doubling (2-fold) or a tripling (3-fold); it is a more than eightfold accumulation. At such high levels, repaglinide becomes much more potent and much more likely to cause adverse effects.

Why this matters for your blood sugar

Repaglinide is a medication that works by stimulating your pancreas to release insulin. It is used in type 2 diabetes to help control blood sugar after meals. At normal doses, this effect is therapeutic and beneficial. However, at 8.1-fold higher exposure, the drug's blood-sugar-lowering effect can become excessive, potentially causing severe hypoglycemia (dangerously low blood sugar). Severe hypoglycemia can lead to confusion, loss of consciousness, seizures, or even death if left untreated.

This is why the interaction is contraindicated rather than merely "monitored closely." The magnitude of the exposure increase makes it difficult to manage safely, even with close medical oversight.

Who Should Pay Particular Attention

If you have ever been prescribed both gemfibrozil and repaglinide, or if you are currently taking them, you are at direct risk from this interaction. Additionally, be aware if:

• You have type 2 diabetes and are on repaglinide for blood sugar control
• You have high triglycerides or cholesterol and have been prescribed gemfibrozil
• You have kidney or liver disease, which can already slow drug metabolism and increase your sensitivity to medication interactions
• You are elderly, as older adults often take multiple medications and may be more sensitive to blood sugar fluctuations

The good news is that this interaction is well-documented and documented medicines often have established alternatives. Your pharmacist or physician can help you find a different cholesterol-lowering agent or a different blood-sugar medication that does not have this dangerous interaction.

Hypothetical Example: How This Interaction Could Play Out

Scenario (hypothetical): Suppose you have type 2 diabetes and high triglycerides. Your doctor prescribes repaglinide 2 mg three times daily before meals to help control your blood sugar, and you do well on it for several months. Later, your triglyceride levels rise, and your doctor adds gemfibrozil 600 mg twice daily. Neither your doctor nor pharmacist catches the interaction, and no one changes your repaglinide dose. Within a few days, you begin to feel dizzy, sweaty, and confused—signs of hypoglycemia. You check your blood sugar and it is dangerously low. You treat it, but the problem persists because every dose of repaglinide is now being processed much more slowly due to gemfibrozil's enzyme inhibition. Your repaglinide exposure is approximately 8 times what it should be, and your pancreas is flooding your bloodstream with insulin in response to excessive drug levels.

In this scenario, the solution is to stop one drug or switch to an alternative. The interaction is not manageable by simply checking your blood sugar more often; the fundamental pharmacokinetic problem requires a change in your medication regimen.

Why alternatives exist: Fortunately, there are other fibrates (e.g., fenofibrate) and other diabetes medications (e.g., metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists) that do not have this same interaction with gemfibrozil, or that have less severe interactions. Your healthcare team can evaluate which option is safest and most effective for your individual situation.

What to Discuss With a Pharmacist or Physician

If you are taking or considering both gemfibrozil and repaglinide, here are the key questions to ask:

1. "Are there any concerns with me taking both gemfibrozil and repaglinide together?" This gives your healthcare provider a chance to confirm whether they are aware of the interaction or whether it was an oversight. If they say they are aware and recommend continuing both, ask them to explain their reasoning—it may be a documentation error or a misunderstanding.
2. "What are my alternatives if I need a cholesterol medication?" Ask about other fibrates (such as fenofibrate, which has a different interaction profile) or non-fibrate options like statins, which do not have the same CYP2C8 inhibition.
3. "What are my alternatives if I need a diabetes medication?" If repaglinide is the best blood-sugar medication for you, ask whether you really need the gemfibrozil or whether your cholesterol can be managed differently.
4. "If I am currently taking both, what should I do?" Do not stop either medication without guidance, as stopping suddenly can cause rebound blood sugar elevation or worsening cholesterol levels. Ask your doctor or pharmacist for a step-by-step plan, which may include switching one medication and then monitoring your blood sugar or lipid levels to ensure the new regimen is working.
5. "How often should my blood sugar be checked?" If you are on repaglinide for any reason, understanding your monitoring schedule helps you catch any abnormal patterns early.

These questions help you and your healthcare team work together to manage your health safely without relying on a contraindicated drug combination.

Key Takeaways

• Gemfibrozil and repaglinide are contraindicated (should not be used together) because gemfibrozil blocks the enzyme CYP2C8, which normally breaks down repaglinide.
• This enzyme inhibition causes repaglinide levels to increase approximately 8.1-fold, creating a serious risk of excessive low blood sugar (hypoglycemia).
• If you are currently taking both medications, do not stop either one on your own; contact your pharmacist or physician immediately to discuss alternatives.
• Other cholesterol-lowering medications (such as fenofibrate or statins) and other diabetes medications are available that do not have this dangerous interaction.
• This interaction is well-documented in FDA drug labeling, making it predictable and avoidable with proper medication review and coordination between your healthcare providers.

Sources

• U.S. Food and Drug Administration (FDA) Drug Information — for access to official drug labeling and FDA-approved prescribing information
• DailyMed (National Library of Medicine) — searchable database of FDA drug labels and patient information sheets
• RxNorm (National Library of Medicine) — standardized nomenclature for clinical drugs and drug interactions
• PubMed (National Library of Medicine) — biomedical literature database for peer-reviewed studies on drug interactions and pharmacokinetics

The interaction information in this article is based on FDA drug labeling for repaglinide as the source of record. For the most current and complete information about this interaction, consult the official prescribing information available through DailyMed or speak with your pharmacist or physician.

Ready to check for drug interactions in your current medication list? Visit checkdruginteractions.com to search your medications and receive a personalized interaction report. Always confirm any medication changes—starting, stopping, or switching—with your pharmacist or physician before making them. Your healthcare team has access to your full medical history and can guide you safely.